Does tacrolimus cause hair loss? Yes — alopecia is listed as a common adverse effect of tacrolimus in its UK prescribing information, affecting an estimated 1 in 10 to 1 in 100 people. Tacrolimus is a calcineurin inhibitor widely used following solid organ transplantation and in certain autoimmune conditions. However, hair loss in this patient group is rarely straightforward: multiple medications, nutritional deficiencies, thyroid dysfunction, and the physiological stress of transplantation can all contribute. This article examines the evidence, explores other contributing factors, and outlines when to seek medical advice.
Summary: Tacrolimus can cause hair loss — alopecia is classified as a common adverse effect in its UK Summary of Product Characteristics, estimated to affect 1 in 10 to 1 in 100 users.
- Tacrolimus is a calcineurin inhibitor used as an immunosuppressant after solid organ transplantation and in certain autoimmune conditions.
- Alopecia is listed as a common adverse effect in the UK SmPCs for Prograf and Advagraf, with an estimated incidence of 1–10%.
- Tacrolimus may be associated with a higher rate of alopecia than ciclosporin, which is more commonly linked to excessive hair growth (hypertrichosis).
- Hair loss in transplant patients is multifactorial — other immunosuppressants, nutritional deficiencies, thyroid dysfunction, and telogen effluvium can all contribute.
- No changes should be made to tacrolimus or any immunosuppressant without direct medical supervision due to the risk of organ rejection.
- Suspected side effects from tacrolimus can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Tacrolimus and Hair Loss: What the Evidence Shows
Alopecia is a recognised adverse effect of tacrolimus, confirmed in UK SmPCs for Prograf and Advagraf; the precise mechanism is not fully established but may involve disruption of hair follicle cycling via calcineurin inhibition.
Experiencing these side effects? Our pharmacists can help you navigate them →
Tacrolimus is a calcineurin inhibitor widely used as an immunosuppressant following solid organ transplantation — including kidney, liver, and heart transplants — as well as in the management of certain autoimmune conditions. It works by inhibiting the activity of calcineurin, a protein involved in activating T-lymphocytes, thereby suppressing the immune response and reducing the risk of organ rejection or immune-mediated tissue damage.
Hair loss (alopecia) is listed as a known adverse effect of tacrolimus in its UK prescribing information. The Summaries of Product Characteristics (SmPCs) for both Prograf and Advagraf, available via the MHRA/electronic Medicines Compendium (eMC), confirm alopecia as a recognised adverse reaction. The precise mechanism by which tacrolimus may contribute to hair loss is not fully established. One hypothesis is that calcineurin signalling plays a role in regulating the hair follicle growth phase (anagen), and that its inhibition may disrupt normal follicular cycling — however, this remains a theoretical explanation and the evidence is limited and inconclusive.
It is important to note that the relationship between tacrolimus and hair loss is not straightforward. Hair loss in transplant recipients and patients on long-term immunosuppression is multifactorial, and attributing it solely to tacrolimus requires careful clinical assessment. Regarding topical tacrolimus (used in conditions such as eczema): whilst it has not been consistently associated with hair loss, some small studies have explored its potential in certain forms of alopecia. This use is off-label, the evidence base is limited, and it should only be considered under specialist dermatology guidance — it is not an established clinical practice.
| Side Effect / Factor | Frequency / Likelihood | Severity | Management |
|---|---|---|---|
| Alopecia (tacrolimus — Prograf / Advagraf) | Common: 1 in 10 to 1 in 100 people (≥1% to <10%), per MHRA/eMC SmPC | Mild to moderate; diffuse thinning; rarely complete baldness | Review trough levels; consider dose reduction or switch under specialist supervision |
| Hypertrichosis (ciclosporin — Neoral / Sandimmun) | Common; more frequently reported than alopecia with ciclosporin | Mild to moderate; excessive hair growth rather than loss | Switching from tacrolimus to ciclosporin may worsen hair growth; discuss with transplant team |
| Alopecia (mycophenolate mofetil — CellCept) | Recognised adverse effect per UK SmPC; exact incidence varies | Mild to moderate | Difficult to isolate from tacrolimus in combination regimens; specialist review required |
| Hair thinning (corticosteroids, e.g. prednisolone) | Recognised; common in long-term use | Mild to moderate | Minimise steroid dose where clinically safe; address via transplant team |
| Telogen effluvium (post-transplant physiological stress) | Common in months following major surgery or serious illness | Temporary; often self-limiting | Reassurance; correct nutritional deficiencies; monitor for resolution |
| Nutritional deficiencies (ferritin, zinc, vitamin D, B12, folate) | Frequently observed post-transplant | Mild to moderate hair shedding; reversible if corrected | GP blood tests (FBC, ferritin, TFTs, vitamin D, B12, folate, zinc); supplement as guided by results |
| Thyroid dysfunction (hypothyroidism / hyperthyroidism) | Well-established cause of diffuse hair loss; prevalence increased in chronic illness | Moderate; reversible with treatment | Thyroid function tests via GP; treat underlying thyroid disorder accordingly |
How Common Is Hair Loss Among Tacrolimus Users
Alopecia is classified as a common adverse effect of tacrolimus, estimated to affect 1 in 100 to 1 in 10 users based on clinical trial and post-marketing data.
According to the UK MHRA/eMC SmPCs for tacrolimus (Prograf and Advagraf), alopecia is classified as a common adverse effect, meaning it is estimated to affect 1 in 100 to 1 in 10 people (≥1% to <10%) taking the medication. This classification is based on data from clinical trials and post-marketing surveillance, though the precise incidence varies across different patient populations and transplant types.
In practice, the degree of hair loss experienced by patients can range considerably — from mild thinning or increased shedding to more noticeable diffuse hair loss. It does not typically cause complete baldness. In some patients, hair loss may stabilise or partially improve over time, particularly following clinical review and any appropriate adjustment to the immunosuppressive regimen, though this is not a predictable outcome and should not be assumed without medical assessment.
Not sure if this is normal? Chat with one of our pharmacists →
It is also worth highlighting that hair loss is reported across several immunosuppressant medications used in transplant medicine, making it difficult to isolate tacrolimus as the sole causative agent in patients receiving combination therapy. Observational data and comparative transplant studies suggest that tacrolimus may be associated with a higher rate of alopecia than ciclosporin, whereas ciclosporin (as documented in its UK SmPC, e.g., Neoral or Sandimmun) is more commonly linked to hypertrichosis (excessive hair growth). This distinction can sometimes inform clinical decision-making when hair-related side effects are a significant concern for the patient, though any switch between immunosuppressants must be made under specialist supervision.
Other Medications and Factors That Can Affect Hair
Hair loss in transplant patients is often multifactorial; mycophenolate mofetil, corticosteroids, nutritional deficiencies, thyroid dysfunction, and telogen effluvium can all contribute independently of tacrolimus.
Patients taking tacrolimus — particularly transplant recipients — are rarely on a single medication. The broader immunosuppressive regimen typically includes agents such as mycophenolate mofetil, corticosteroids (e.g., prednisolone), and mTOR inhibitors (e.g., sirolimus or everolimus), all of which have been independently associated with hair changes, as documented in their respective UK SmPCs. Mycophenolate mofetil (e.g., CellCept) lists alopecia as a recognised adverse effect, and corticosteroids can contribute to hair thinning through their effects on the hair growth cycle and scalp health.
Beyond medication, several other factors commonly seen in transplant patients and those with chronic illness can contribute to hair loss:
-
Nutritional deficiencies — including low iron (ferritin), zinc, vitamin D, vitamin B12, or folate — are frequently observed post-transplant and can significantly affect hair health. Where clinically indicated, testing for zinc, B12, and folate alongside ferritin is reasonable practice.
-
Thyroid dysfunction — both hypothyroidism and hyperthyroidism — is a well-established cause of diffuse hair loss and should be excluded with appropriate blood tests.
-
Telogen effluvium — a temporary but often distressing form of hair shedding triggered by physiological stress such as major surgery, serious illness, or significant weight change — is particularly common in the months following transplantation.
-
Androgenetic alopecia — the most common form of hair loss in the general population — may be unmasked or accelerated by systemic illness or medication.
Understanding these contributing factors is essential before attributing hair loss exclusively to tacrolimus, as addressing an underlying nutritional deficiency or thyroid imbalance may lead to meaningful improvement without any change to the immunosuppressive regimen.
A note on biotin: whilst biotin deficiency can contribute to hair loss, patients should not self-start high-dose biotin supplements without first discussing this with their clinical team. The MHRA has issued advice that high-dose biotin can interfere with a range of laboratory tests (including thyroid function and troponin assays), potentially leading to misleading results. Any supplementation should be clinician-guided.
When to Speak to Your GP or Transplant Team
Seek prompt medical advice for rapid, patchy, or extensive hair loss, scalp changes suggesting scarring alopecia, or hair loss accompanied by symptoms such as fatigue or weight change.
Hair loss, while rarely medically dangerous in itself, can have a significant impact on a patient's quality of life, self-esteem, and psychological wellbeing. It is always appropriate to raise concerns about hair loss with your GP or transplant team, particularly if the shedding is sudden, severe, or accompanied by other symptoms.
You should seek prompt medical advice if you notice:
-
Rapid or extensive hair loss occurring over a short period
-
Patchy hair loss (which may suggest alopecia areata, a separate autoimmune condition)
-
Scalp changes such as redness, scaling, itching, soreness, pustules, or crusting — or if the follicular openings appear to be disappearing — as these may be signs of scarring (cicatricial) alopecia, which requires early dermatology review to prevent permanent hair loss
-
Hair loss alongside other new symptoms, such as fatigue, weight changes, or feeling unusually cold — which could indicate thyroid dysfunction
-
Significant distress related to changes in your appearance
Your transplant team is best placed to review your current immunosuppressive regimen and assess whether a dose adjustment or switch to an alternative agent might be appropriate. As part of this review, they may check your tacrolimus trough levels, since supratherapeutic levels can increase the risk of adverse effects. They will also consider whether any interacting medicines — such as azole antifungals, macrolide antibiotics, or certain calcium-channel blockers — or dietary factors such as grapefruit consumption may be affecting tacrolimus levels. It is crucial that no changes are made to tacrolimus or any other immunosuppressant without direct medical supervision, as doing so carries a risk of organ rejection or disease flare.
Your GP can assist by arranging relevant blood tests — including full blood count, ferritin, thyroid function, vitamin D, and where clinically indicated, B12, folate, and zinc — to help identify any treatable underlying causes. In some cases, referral to a dermatologist with experience in hair disorders may be warranted, particularly if scarring alopecia is suspected or the cause remains unclear after initial investigation.
If you believe you have experienced a side effect from tacrolimus or any other medicine, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.
Managing Hair Loss While Taking Tacrolimus
Management begins with identifying and correcting modifiable causes such as nutritional deficiencies; dose adjustment or switching immunosuppressant may be considered by the transplant team on an individual basis.
For many patients, hair loss associated with tacrolimus is manageable and does not require a change in medication. The first step is a thorough assessment to identify and address any modifiable contributing factors. Correcting nutritional deficiencies — particularly iron (ferritin), zinc, vitamin D, B12, and folate — through dietary changes or supplementation (guided by blood test results and clinician advice) can make a meaningful difference to hair health over time.
From a practical standpoint, the following measures may help to minimise further hair damage and support scalp health:
-
Use gentle, sulphate-free shampoos and avoid harsh chemical treatments such as bleaching, perming, or excessive heat styling
-
Avoid tight hairstyles (such as tight ponytails or braids) that place mechanical stress on hair follicles
-
Handle hair gently when washing and drying — pat rather than rub with a towel
-
Maintain a balanced diet rich in protein, leafy vegetables, and foods containing iron and zinc
If hair loss is felt to be directly related to tacrolimus, your transplant team may consider whether a dose reduction is clinically safe, or whether switching to an alternative immunosuppressant is appropriate given your overall clinical picture. There is no specific NICE guidance addressing tacrolimus-induced alopecia, and management decisions are therefore made on an individual basis.
Topical minoxidil is licensed in the UK for androgenetic alopecia (male and female pattern hair loss) and is available without prescription for this indication. Its use for other causes of hair loss is off-label and should be clinician-led. Minoxidil should be avoided during pregnancy and breastfeeding unless a specialist has specifically advised otherwise; patients should review the NHS Medicines A–Z entry for topical minoxidil and discuss suitability with their medical team before starting.
Patients may also wish to ask their clinical team about access to NHS wigs or hairpieces, where eligible, and about referral to psychology or counselling services. Hair loss can be deeply distressing, and patients deserve holistic care that addresses both the physical and emotional dimensions of this side effect.
Frequently Asked Questions
Does tacrolimus cause hair loss?
Yes. Alopecia is classified as a common adverse effect of tacrolimus in its UK Summary of Product Characteristics, estimated to affect between 1 in 100 and 1 in 10 people taking the medication. Hair loss is typically diffuse rather than complete baldness.
Will stopping tacrolimus reverse hair loss?
You must never stop or alter your tacrolimus dose without medical supervision, as this carries a serious risk of organ rejection. Your transplant team can assess whether a dose adjustment or switch to an alternative immunosuppressant is clinically appropriate.
Is hair loss from tacrolimus permanent?
Hair loss associated with tacrolimus is not typically permanent and may stabilise or partially improve over time, particularly if contributing factors such as nutritional deficiencies or thyroid dysfunction are identified and treated. Scarring alopecia, which can cause permanent loss, requires early specialist dermatology review.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
